Last reviewed · How we verify

NCT04702113: CARES2

Evaluating Pharmacogenomic Variants for Cardiology Therapeutics

Completed NA Last updated 29 September 2023
What this trial tests

NA trial testing Cipherome Lighthouse Pilot in Thrombosis in 300 participants. Completed in 27 July 2023.

Timeline
3 December 2020
Primary endpoint
26 July 2023
27 July 2023

Quick facts

Lead sponsorCipherome, Inc.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposediagnostic
Enrollment300
Start date3 December 2020
Primary completion26 July 2023
Estimated completion27 July 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Cipherome, Inc.

Who can join

Adults 18 to 99, any sex, with Thrombosis or Stent Thrombosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cipherome's Lighthouse is a clinical decision support tool that incorporates a patient's pharmacogenetic information to determine therapeutic strategy, including determining appropriate dosage or assessing the likelihood of toxicity of a therapeutic regimen.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Thrombosis

Currently open trials in the same condition.

Other Cipherome, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04702113.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing